ST14 interacts with TMEFF1 and is a predictor of poor prognosis in ovarian cancer.

"Declarations Ethics approval and concent for participateThe study was approved by the Research Ethics Board at Shengjing Hospital of China Medical University (Shenyang, China, approval no. 2020PS275K). All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained from all individual participants included in the study. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by the National Natural Science Foundation of China [No. 82173130, 81672590, 81472437]; Outstanding Scientific Fund of Shengjing Hospital [No. 201804]; Key R&D Guidance Plan Project in Liaoning Province (2019JH8/10300022); Beijing Kanghua Foundation for the Development of Traditional Chinese and Western Medicine Gynecological Oncology Special Research Fund (KH-2021-LLZX-010); 345 talents project of Shengjing Hospital(M1374); Scientific Fund of Shengjing Hospital(M1117)."